The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Neotrace: A multicenter phase II study of neoadjuvant sacituzumab govitecan plus zimberelimab followed by adjuvant zimberelimab with or without sacituzumab govitecan in patients with resectable non-small cell lung cancer.
 
Friederike Althoff
Honoraria - Amgen; Roche
Consulting or Advisory Role - IQVIA
Research Funding - Novartis
Travel, Accommodations, Expenses - Amgen
 
Fabian Acker
Consulting or Advisory Role - F.A. reports having received support for attending meetings from AstraZeneca, Amgen, and Daiichi-Sankyo, speaker’s honoraria from AstraZeneca, and Amgen, and consultant fees from IQVIA, Novartis, and NovoCure.
Travel, Accommodations, Expenses - F.A. reports having received support for attending meetings from AstraZeneca, Amgen, and Daiichi-Sankyo, speaker’s honoraria from AstraZeneca, and Amgen, and consultant fees from IQVIA, Novartis, and NovoCure.
 
Sebastian Koschade
No Relationships to Disclose
 
Sophie Heinzen
No Relationships to Disclose
 
Lukas Aguinarte
No Relationships to Disclose
 
Maximilian Rost
No Relationships to Disclose
 
Hanna Schulte
No Relationships to Disclose
 
Gernot Rohde
Consulting or Advisory Role - G.R. reports personal fees from Astra Zeneca, Atriva, Boehringer Ingelheim, GSK, Insmed, MSD, Sanofi, Novartis and Pfizer for consultancy during advisory board meetings and reports personal fees from Astra Zeneca, Berlin Chemie, BMS, Boehringer Ingelheim,
 
Melanie Demes
No Relationships to Disclose
 
Waldemar Schreiner
No Relationships to Disclose
 
Katrin Krause
No Relationships to Disclose
 
Viktor Grünwald
Employment - University Hospital Essen
Stock and Other Ownership Interests - Amgen; AstraZeneca; Bicycle Therapeutics; Bristol-Myers Squibb; Genmab; MSD
Honoraria - Advanced Accelerator Applications/Novartis; Amgen; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; Gilead Sciences; Ipsen; Johnson & Johnson/Janssen; Merck Serono; MSD Oncology; Roche; Telix Pharmaceuticals
Consulting or Advisory Role - Bristol-Myers Squibb; Debiopharm Group; Eisai; Gilead Sciences; Ipsen; Janssen-Cilag; MSD Oncology; Novartis; Oncorena; Pfizer; Recordati; Synthekine
Research Funding - Amgen (Inst); Bicycle Therapeutics (Inst); BMS (Inst); Exelixis (Inst); Gilead Sciences (Inst); Ipsen (Inst); Johnson & Johnson/Janssen (Inst); MSD Oncology (Inst); Novartis (Inst); Roche (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Ipsen; Janssen; Merck Serono; Pfizer
 
Hubert Serve
Stock and Other Ownership Interests - Arvin; Biontech; Intellia Therapeutics; Kymera
Honoraria - Gilead Sciences; Gilead Sciences; Novartis; Robert-Bosch-Gesellschaft für Medizinische Forschung mbH
Consulting or Advisory Role - Abbvie; Gilead Sciences; IKP Stuttgart
Patents, Royalties, Other Intellectual Property - COMPANION DIAGNOSTICS FOR LEUKEMIA TREATMENT (Inst); MARKERS FOR RESPONSIVENESS TO AN INHIBITOR OF FLT3; Patent on Oncogene Redirection; Patent on Samhd1 modulation for treating resistance to cancer therapy (Inst)
 
Thomas Oellerich
Consulting or Advisory Role - T.O. reports having received research funding from Gilead and Merck KGaA, consultation fees from Beigene, Roche, Janssen, Merck KGaA, Gilead, Kronos Bio, and Abbvie.
Research Funding - T.O. reports having received research funding from Gilead and Merck KGaA, consultation fees from Beigene, Roche, Janssen, Merck KGaA, Gilead, Kronos Bio, and Abbvie.
 
Martin Sebastian
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Merck KGaA; MSD; Novartis; Pfizer; Pierre Fabre; Regeneron; Sanofi; Takeda
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Daiichi Sankyo; Gilead Sciences; Pfizer; Pierre Fabre; Regeneron; Sanofi; Takeda
Research Funding - AstraZeneca (Inst); Gilead Sciences (Inst)
Travel, Accommodations, Expenses - Merck; Pfizer; Takeda